Business Wire

GOTO-GROUP

Share
GoTo Completes Landmark Listing on the Indonesia Stock Exchange

PT GoTo Gojek Tokopedia Tbk (“GoTo Group'' or the “Company”), the largest digital ecosystem in Indonesia, today announced its listing on the Main Board of the Indonesia Stock Exchange (IDX), where its shares will trade under the stock code GOTO. The total amount raised from the Group’s Initial Public Offering (IPO) process is approximately USD1.1 billion (IDR15.8 trillion), comprising USD954.7 million (IDR13.7 trillion) in proceeds plus USD146.3 million (IDR2.1 trillion) from treasury shares for the purpose of over allotment, representing a market capitalisation of approximately USD28 billion (IDR400.3 trillion).

Based on the total funds raised, GoTo’s IPO is the third largest in Asia and fifth largest in the world this year.1 Around 300,000 investors have participated - the highest ever number to take part in an IPO on the IDX.

As part of the drive to make this IPO one of the most inclusive, GoTo has introduced the Gotong Royong Share Program. The company has allocated over US$20 million2 to driver-partners, as well as forming the GoTo Future Fund - an endowment fund that aims to support initiatives and solutions that benefit the lives of stakeholders across the GoTo ecosystem. Loyal merchants and consumers in Indonesia were able to benefit from the IPO, receiving priority access to order a fixed allocation of GoTo shares. Furthermore, as part of the program, all full time employees have been made participants in the Group's Long-Term Incentive Plan.

Andre Soelistyo, GoTo Group CEO said , “Today we embark on a new journey as a public company. Our listing on the Indonesia Stock Exchange will strengthen our ability to pursue our mission and better serve customers. Despite global market volatility, investor interest has been strong, reflecting the rapidly growing demand in Southeast Asia for our on-demand, e-commerce and financial technology services, as well as confidence in GoTo's position as the largest digital ecosystem in Indonesia.

“Ultimately, the people who deserve the most recognition for today's milestone are the people who worked so hard to breathe life into our business. Our success can be wholly attributed to our driver-partners, merchants, consumers and employees, and it was therefore a priority for us to ensure they could benefit from our IPO via the Gotong Royong Share Program, one of the most inclusive share ownership programs in the world today. With all of these groups working together, we are truly unstoppable as we pursue our mission to empower progress for Indonesia and Southeast Asia.

“I would also like to express our gratitude to the Government of Indonesia, the OJK, and IDX for their support during the IPO process, and for their continued commitment to the growth of Indonesia’s digital economy. Together we can help to support Indonesia’s digital transformation by leveraging technology for the benefit of all.”

The listing ceremony and the handover of the listing certificate took place today at the Indonesia Stock Exchange, in Jakarta, and was attended by Coordinating Minister for Economic Affairs Airlangga Hartarto, Chairman of the Board of Commissioners of OJK Wimboh Santoso, and IDX’s President Director Inarno Djajadi.

GoTo Group’s listing represents a historic moment for the Company and the IDX, as the first listing to be carried out under the new regulations on multiple voting rights set out by the OJK. The Company offered a total of 46.7 billion Series A shares, comprising newly issued, and treasury shares (for the purpose of over allotment) at an offer price of IDR338, representing a projected market capitalization of approximately USD28 billion (IDR400.3 trillion) at admission.

A long-term strategy for growth

GoTo Group plans to use the proceeds from the IPO, after deducting issuance costs, for working capital to support the Company’s growth strategy, comprising four pillars:

  1. Driving customer growth and engagement through cross pollination and by increasing usage among consumers, merchants and driver-partners.
  2. Enhancing hyperlocal experiences and infrastructure to provide consumers with more convenience in their digital daily lives.
  3. Strengthening ecosystem synergies including enhanced loyalty and rewards programs, deeper financial services offerings and further development of value added merchant services.
  4. Investing in high growth areas , including deeper demographic expansion in Indonesia, Singapore and Vietnam, targeted strategic investments, investment in technology and infrastructure, and the transition towards electric vehicles.

GoTo Group is the market leader in Indonesia in each of its business verticals and by strengthening the synergies and network effects from within its ecosystem, the Group is well positioned for continued growth. GoTo Group has already achieved:

  • Pro forma3 Gross Transaction Value (GTV) of IDR414.2 trillion (USD28.8 billion) in the 12-months ended 30 September 2021
  • Pro forma Gross Revenue of IDR15.1 trillion (USD1 billion) in the 12-months ended 30 September 2021
  • Pro forma Orders of approximately 2 billion in the 12-months ended 30 September 2021
  • Over 55 million annual transacting users (ATU) on a pro forma basis, as of 30 September, 2021
  • Over 2.5 million registered driver partners, as of 30 September, 2021
  • Over 14 million registered merchants, as of 30 September, 2021

Indonesia represents Southeast Asia’s largest economy, contributing a GDP of more than USD1 trillion and a population of 274 million - the fourth largest in the world. Indonesia and Southeast Asia have a young and highly tech-savvy population with increasing spending power that is driving the growth of the region’s digital economy.

Growing demand for services across GoTo Group’s ecosystem, driven by increasing digital adoption among consumers in Southeast Asia, has underpinned the Group’s strong financial performance in recent years. GoTo Group’s pro forma GTV grew at 46% CAGR between 2018 and 2020, and at 62% YoY between Q3 2020 and Q3 2021. Pro forma gross revenue grew at 56% CAGR between FY2018 and FY2020 and 55% YoY between Q3 2020 and Q3 2021.

PT Indo Premier Sekuritas, PT Mandiri Sekuritas, and PT Trimegah Sekuritas Indonesia Tbk acted as the Joint Lead Underwriters for the IPO.

Notes to editors:
https://www.gotocompany.com/investor-relations/prospectus
For more information on GoTo and the IPO, please see the Prospectus at gotocompany.com.

Definition of pro-forma : The pro forma information of GTV, Orders, ATU and gross revenue provided is as if Tokopedia had been consolidated by GoTo since January 1, 2018.

Exchange rate: IDR14.350 = USD1

About GoTo Group:

PT GoTo Gojek Tokopedia Tbk (GoTo Group) is the largest digital ecosystem in Indonesia. GoTo's mission is to "empower progress" by offering technology infrastructure and solutions that help everyone to access and thrive in the digital economy. The GoTo ecosystem consists of on-demand services (mobility, food delivery, and logistics), e-commerce (third party marketplaces + official stores, instant commerce, interactive commerce, and rural commerce), and financial technology (payments, financial services, and technology solutions for merchants) through the Gojek, Tokopedia, and GoTo Financial platforms.

___________________________
1 Source: Bloomberg
2 Value based on opening share price of IDR 338 per share
3 See notes to editors for pro forma definition.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye